You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

CLINICAL TRIALS PROFILE FOR CELEXA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Celexa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018902 ↗ Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) Completed National Institute of Mental Health (NIMH) Phase 2/Phase 3 2001-01-01 The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
NCT00018902 ↗ Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) Completed University of Pittsburgh Phase 2/Phase 3 2001-01-01 The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
NCT00044798 ↗ Magnetic Stimulation Therapy for Treating Vascular Depression Completed National Institute of Mental Health (NIMH) Phase 3 2001-09-01 This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) of the brain, followed by citalopram (Celexa®), for treatment of depression associated with small vascular lesions in the brain (vascular depression).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Celexa

Condition Name

Condition Name for Celexa
Intervention Trials
Major Depressive Disorder 11
Depression 11
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Celexa
Intervention Trials
Depression 29
Depressive Disorder 24
Depressive Disorder, Major 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Celexa

Trials by Country

Trials by Country for Celexa
Location Trials
United States 106
Canada 6
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Celexa
Location Trials
California 14
New York 13
Pennsylvania 9
Massachusetts 8
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Celexa

Clinical Trial Phase

Clinical Trial Phase for Celexa
Clinical Trial Phase Trials
Phase 4 14
Phase 3 5
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Celexa
Clinical Trial Phase Trials
Completed 46
Withdrawn 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Celexa

Sponsor Name

Sponsor Name for Celexa
Sponsor Trials
National Institute of Mental Health (NIMH) 24
New York State Psychiatric Institute 7
University of Pittsburgh 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Celexa
Sponsor Trials
Other 52
NIH 33
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Celexa (Citalopram Hydrobromide): Clinical Trials Update, Market Analysis, and Projections

Introduction to Celexa

Celexa, known generically as citalopram hydrobromide, is a selective serotonin reuptake inhibitor (SSRI) primarily used for the treatment of major depressive disorder (MDD), as well as anxiety disorders. Here, we will delve into the current clinical trials, market analysis, and future projections for this medication.

Clinical Trials Update

Ongoing and Recent Trials

Several clinical trials involving citalopram and its enantiomer escitalopram are ongoing or have recently concluded:

Escitalopram in Alzheimer's Disease

A Phase 3 trial, known as S-CitAD, was conducted to evaluate the efficacy of escitalopram in treating agitation in patients with Alzheimer's disease. The trial, which began in January 2018 and concluded in November 2023, failed to meet its primary endpoint of showing marked improvement on the ADCS-Clinical Global Impression of Change scale. However, escitalopram did not cause cognitive worsening, a significant concern with many antidepressants in this patient population[4].

Effects on Aβ Dynamics

A trial initiated in February 2022 is assessing the effects of escitalopram on amyloid-beta (Aβ) dynamics in adults with major depression. This study aims to evaluate changes in cerebrospinal fluid (CSF) Aβ40, Aβ42, and other biomarkers, as well as depressive symptoms, in participants aged 60 and older. The trial is expected to run until early 2026[4].

Safety and Efficacy Studies

Previous studies have highlighted the safety and efficacy concerns associated with citalopram. For instance, the FDA has announced safety labeling changes to Celexa, including new dosage recommendations and warnings for higher risks of adverse reactions in pediatric and geriatric populations, as well as sexual dysfunction in both male and female patients[1].

Market Analysis

Market Size and Growth Projections

The global citalopram hydrobromide market is anticipated to experience significant growth from 2024 to 2031. Here are some key projections:

  • Market Size: The market was valued at approximately USD 118.3 million in 2022 and is expected to grow at a remarkable Compound Annual Growth Rate (CAGR) during the forecast period[5].
  • Revenue Growth: The market is projected to develop substantial revenue, with exponential market growth expected from 2024 to 2031. This growth is driven by increasing demand for antidepressants and the expanding global healthcare market[5].

Segmentation and Analysis

The citalopram hydrobromide market is segmented based on several key factors:

By Type

The market can be segmented into branded and generic versions of citalopram hydrobromide. Generic versions are expected to play a significant role in the market, especially in regions where patent expirations have led to the availability of cheaper alternatives[5].

By Geography

The global market is segmented geographically, with significant growth expected in regions such as North America, Europe, and Asia-Pacific. The Asia-Pacific region, particularly China, is anticipated to show rapid growth due to increasing healthcare spending and a growing population[5].

Market Drivers and Barriers

Drivers of Growth

Several factors are driving the growth of the citalopram hydrobromide market:

  • Increasing Prevalence of Depression: The rising incidence of major depressive disorder and other psychiatric conditions is a major driver of the market.
  • Expanding Healthcare Infrastructure: Improvements in healthcare infrastructure and increased access to mental health services are contributing to market growth.
  • Generic Competition: The availability of generic versions of citalopram hydrobromide is making the medication more accessible and affordable, thereby driving market growth[5].

Barriers to Growth

Despite the positive outlook, there are several barriers to growth:

  • Patent Expirations: The expiration of patents for branded versions of citalopram hydrobromide can lead to increased competition from generics, potentially reducing revenue for branded products.
  • Side Effects and Safety Concerns: The FDA's recent safety labeling changes highlight the need for careful monitoring and management of side effects, which can impact patient compliance and market growth[1][3].

Competitive Landscape

The antidepressant market, including SSRIs like citalopram hydrobromide, is highly competitive. Key players include pharmaceutical companies that produce both branded and generic versions of these medications. The market is also influenced by the presence of other antidepressant classes, such as selective norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs)[5].

Future Projections

Market Forecast

By 2031, the global citalopram hydrobromide market is expected to achieve significant revenue growth, driven by the factors mentioned above. Here are some key projections:

  • Market Size: The market is expected to grow substantially, with a projected CAGR that reflects the increasing demand for antidepressants.
  • Geographical Expansion: The market is expected to expand geographically, with Asia-Pacific regions showing the most rapid growth[5].

Emerging Trends

Emerging trends in the market include the increasing focus on personalized medicine and the development of new formulations that improve patient compliance and reduce side effects. Additionally, the integration of digital health technologies to monitor and manage mental health conditions is expected to play a significant role in the future of the antidepressant market[5].

Key Takeaways

  • Clinical Trials: Ongoing and recent trials have focused on the efficacy and safety of escitalopram in various patient populations, including those with Alzheimer's disease.
  • Market Growth: The global citalopram hydrobromide market is expected to grow significantly from 2024 to 2031, driven by increasing demand and expanding healthcare infrastructure.
  • Segmentation: The market is segmented by type (branded vs. generic) and geography, with Asia-Pacific regions showing rapid growth.
  • Drivers and Barriers: The market is driven by the increasing prevalence of depression and expanding healthcare infrastructure, but faces barriers such as patent expirations and safety concerns.

FAQs

What is Celexa used for?

Celexa, or citalopram hydrobromide, is primarily used for the treatment of major depressive disorder (MDD) and anxiety disorders.

What are the recent safety labeling changes to Celexa?

The FDA has announced new dosage recommendations and warnings for higher risks of adverse reactions in pediatric and geriatric populations, as well as warnings for sexual dysfunction in both male and female patients[1].

What is the current market size of citalopram hydrobromide?

The global citalopram hydrobromide market was valued at approximately USD 118.3 million in 2022[5].

What are the key drivers of growth for the citalopram hydrobromide market?

The increasing prevalence of depression, expanding healthcare infrastructure, and the availability of generic versions are key drivers of growth[5].

What are the potential barriers to growth for the citalopram hydrobromide market?

Patent expirations and safety concerns are significant barriers to growth for the citalopram hydrobromide market[1][3].

Sources

  1. FDA Announces Safety Labeling Changes to Celexa - Psychiatric Times
  2. NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025 - Drug Development
  3. 020822Orig1s038, s040 021046Orig1s016, s017 - FDA
  4. Citalopram | ALZFORUM - Alzforum
  5. citalopram hydrobromide drug sales trends - DrugPatentWatch
Last updated: 2025-01-07

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.